Vilas Boas Lucy S, de Souza Vanda A Ueda F, Penalva de Oliveira Augusto C, Rodriguez Viso Ana T, Nascimento Filho Anderson M, Nascimento Maria C, Pannuti Cláudio S
Laboratório de Virologia (LIMHC), Instituto de Medicina Tropical de São Paulo, Departamento de Doenças Infecciosas e Parasitárias da Faculdade de Medicina, Universidade de São Paulo, Av. Enéas de Carvalho Aguiar 470, São Paulo 04503-000, Brazil.
J Med Virol. 2003 Nov;71(3):404-7. doi: 10.1002/jmv.10488.
To investigate any association between cytomegalovirus glycoprotein B (CMV gB) subtypes and central nervous system (CNS) disease in AIDS patients, proportions of different gB genotypes detected in AIDS patients with CNS disease were compared with the gB genotypes detected in AIDS patients with no neurological disorder. The patients were matched by CD4+ cell counts. CMV was detected by PCR in cerebrospinal fluid (CSF) samples obtained from AIDS patients with CNS disease and from urine and saliva samples obtained from AIDS patients without CNS disease. CMV strains obtained were digested by restriction enzymes HinffI and RsaI to classify the genotypes. The CMV gB genotype was determined in 26 CSF samples. Of these, 11/26 (42.3%) typed as gB group 1, seven (26.9%) as gB2, four (15.4%) as gB3, and four (15.4%) as gB4. The CMV gB genotype frequency distribution in the 42 AIDS patients without CNS disease showed that 18/42 (42.8%) were classified as gB group 1, 10 (23.8%) as gB2, seven (16.6%) as gB3, and seven (16.6%) as gB4. In the present study, no association was found between CMV gB genotypes and CMV-related central nervous system disease.
